<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04918407</url>
  </required_header>
  <id_info>
    <org_study_id>SBMU98543</org_study_id>
    <nct_id>NCT04918407</nct_id>
  </id_info>
  <brief_title>Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation</brief_title>
  <official_title>Effects of Empagliflozin in Reducing Oxidative Stress of Diabetic Recipients After Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of empagliflozin on oxidative stress&#xD;
      in patients with type 2 diabetes after kidney transplantation. The association is examined by&#xD;
      comparing the difference in oxidative modifications before and after 90 days treatment with&#xD;
      25 mg empagliflozin plus insulin compared to insulin treatment. The study is randomised and&#xD;
      double-blinded. Each treatment group consists of 20 patients. Oxidative stress markers are&#xD;
      measured by serum level of superoxide dismutase activity ,lipid peroxidation assay kit,&#xD;
      glutathione assay, glutathione peroxidase activity , total antioxidant capacity assay oxidant&#xD;
      status , carbonyl content assay and bca protein assay . . A student t-test will be performed&#xD;
      to compare adding empagliflozin . The results will be published in a peer-review journal.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the purpose of studying the antioxidant activity of empagloflozin 25mg will add on&#xD;
      insulin in 20 patients after kidney transplant and will compare with 20 diabetic recipient of&#xD;
      kidney transplant on insulin therapy alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum level of superoxide dismutase</measure>
    <time_frame>Change from baseline after 90 days of intervention</time_frame>
    <description>Serum level of antioxidant levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of malondialdehyde</measure>
    <time_frame>Change from baseline after 90 days of intervention</time_frame>
    <description>Serum level of antioxidant levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Kidney Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adding 25mg Empagliflozin on Insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Just contriling the blood glucose with Insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 25 MG</intervention_name>
    <description>25 mg</description>
    <arm_group_label>Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin</description>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_label>Insulin alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with type 2 diabetes&#xD;
&#xD;
          -  HbA1c: 6.5-9.0%&#xD;
&#xD;
          -  post kidney transplant&#xD;
&#xD;
          -  stable graft function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pancreas and kidney transplant&#xD;
&#xD;
          -  history of recurrent urinary tract infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nooshin Dalili</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nooshin Dalili</last_name>
    <phone>00989122404331</phone>
    <email>nooshindalili4@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nooshin Dalili</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 29, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>nooshin dalili</investigator_full_name>
    <investigator_title>Assistant Professor of SBMU</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

